IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Provided By GlobeNewswire
Last update: Jun 2, 2025
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology
Phase 3 OVATION 3 Study in progress
Read more at globenewswire.com6.5
-0.07 (-1.07%)
Find more stocks in the Stock Screener
IMNN Latest News and Analysis
19 days ago - By: Chartmill
